Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimustine + pegfilgrastim + teniposide
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of nimustine (an alkylating agent), pegfilgrastim (a long-acting granulocyte colony-stimulating factor), and teniposide (a topoisomerase II inhibitor). This combination would likely be used in cancer treatment protocols where nimustine and teniposide provide cytotoxic effects against cancer cells, while pegfilgrastim helps manage chemotherapy-induced neutropenia by stimulating the production of neutrophils.
02
Targets
DNACSF3R (Granulocyte colony-stimulating factor receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on nimustine + pegfilgrastim + teniposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimustine + pegfilgrastim + teniposide.